Intellectual Property Magazine
Baltimore files antitrust suit against Janssen
Karen Beynon
The city of Baltimore is alleging that Janssen, part of theJohnson & Johnson pharmaceutical business, filed “sham litigation”
to staveoff the market entry of cheaper generic versions of its multi-billion-dollar anti-prostatecancer agent, Zytiga (abiraterone
acetate).